The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Cardiac adverse events such as decreased ejection fraction and heart failure have been of particular concern in patients with HER2+breast cancer. Anti-HER2 agents and chemotherapies (specifically anthracyclines, which are frequently used to treat HER2+disease) have been associated with cardiotoxicity. ...
Trastuzumab adds benefit to chemo in HER2+ breast cancer. The article discusses research being done on trastuzumab. It references a study by A. U. Buzdar et al in the January 1, 2007 issue of "Clinical Cancer Rese... - 《Inpharma Weekly》 被引量: 0发表: 2007年 Trastuzumab after adjuva...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
Neoadjuvant chemo is commonly given for: Inflammatory breast cancer HER2-positive breast cancer Triple-negative breast cancer High-grade tumors Large tumors Cancers that have spread to thelymph nodes Adjuvant chemotherapyis given after the primary treatment.It's intended to kill any cancer cells that ...
Breast cancer subtypeReceptor profileSubtype prevalenceSubcategories Hormone positive ER+ or PR+ 60% Luminal A & B HER2 positive HER2+ 20% – Triple negative breast cancer ER−, PR− and HER2− 10–20% Basal-like 1 (BL-1), basal-like 2 (BL-2), immunomodulatory (IM), mesenchyma...
Biologics: Targets & Therapy Dovepress open access to scientific and medical research Open Access Full Text Article HER2 breast cancer therapies: a review review Conleth G Murphy Shanu Modi Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY,...
Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.
MINIREVIEW British Journal of Cancer (2014) 111, 1888–1898 | doi: 10.1038/bjc.2014.388 Keywords: Erbb-2; trastuzumab; pertuzumab; trastuzumab-DM1; lapatinib; breast neoplasm HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development J C Singh1, K ...
HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. HER2 is also overexpressed in ...